GLYC
Price
$0.30
Change
-$0.01 (-3.23%)
Updated
May 8, 6:59 PM EST
One day until earnings call
IONS
Price
$40.16
Change
-$0.77 (-1.88%)
Updated
May 8, 6:59 PM EST
91 days until earnings call
Ad is loading...

GLYC vs IONS

Header iconGLYC vs IONS Comparison
Open Charts GLYC vs IONSBanner chart's image
GlycoMimetics
Price$0.30
Change-$0.01 (-3.23%)
Volume$1.9M
CapitalizationN/A
Ionis Pharmaceuticals
Price$40.16
Change-$0.77 (-1.88%)
Volume$865.86K
CapitalizationN/A
View a ticker or compare two or three
GLYC vs IONS Comparison Chart

Loading...

GLYCDaily Signal changed days agoGain/Loss if shorted
 
Show more...
IONSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
GLYC vs. IONS commentary
May 09, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLYC is a Hold and IONS is a Sell.

COMPARISON
Comparison
May 09, 2024
Stock price -- (GLYC: $0.31 vs. IONS: $40.93)
Brand notoriety: GLYC and IONS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLYC: 434% vs. IONS: 128%
Market capitalization -- GLYC: $19.68M vs. IONS: $5.98B
GLYC [@Biotechnology] is valued at $19.68M. IONS’s [@Biotechnology] market capitalization is $5.98B. The market cap for tickers in the [@Biotechnology] industry ranges from $567.57B to $0. The average market capitalization across the [@Biotechnology] industry is $2.65B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLYC’s FA Score shows that 0 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).

  • GLYC’s FA Score: 0 green, 5 red.
  • IONS’s FA Score: 0 green, 5 red.
According to our system of comparison, IONS is a better buy in the long-term than GLYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLYC’s TA Score shows that 4 TA indicator(s) are bullish while IONS’s TA Score has 3 bullish TA indicator(s).

  • GLYC’s TA Score: 4 bullish, 5 bearish.
  • IONS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, GLYC is a better buy in the short-term than IONS.

Price Growth

GLYC (@Biotechnology) experienced а -83.03% price change this week, while IONS (@Biotechnology) price change was -0.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.98%. For the same industry, the average monthly price growth was -4.81%, and the average quarterly price growth was +71.11%.

Reported Earning Dates

GLYC is expected to report earnings on Aug 01, 2024.

IONS is expected to report earnings on Aug 07, 2024.

Industries' Descriptions

@Biotechnology (+0.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for GLYC with price predictions.
OPEN
A.I.dvisor published
a Summary for IONS with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
IONS($5.98B) has a higher market cap than GLYC($19.7M). IONS YTD gains are higher at: -19.095 vs. GLYC (-87.059).
GLYCIONSGLYC / IONS
Capitalization19.7M5.98B0%
EBITDAN/AN/A-
Gain YTD-87.059-19.095456%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
GLYC vs IONS: Fundamental Ratings
GLYC
IONS
OUTLOOK RATING
1..100
555
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
9862
P/E GROWTH RATING
1..100
10069
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GLYC's Valuation (88) in the Biotechnology industry is in the same range as IONS (96). This means that GLYC’s stock grew similarly to IONS’s over the last 12 months.

GLYC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as IONS (100). This means that GLYC’s stock grew similarly to IONS’s over the last 12 months.

GLYC's SMR Rating (98) in the Biotechnology industry is in the same range as IONS (98). This means that GLYC’s stock grew similarly to IONS’s over the last 12 months.

IONS's Price Growth Rating (62) in the Biotechnology industry is somewhat better than the same rating for GLYC (98). This means that IONS’s stock grew somewhat faster than GLYC’s over the last 12 months.

IONS's P/E Growth Rating (69) in the Biotechnology industry is in the same range as GLYC (100). This means that IONS’s stock grew similarly to GLYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLYCIONS
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
68%
Momentum
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 2 days ago
68%
MACD
ODDS (%)
Bearish Trend 6 days ago
90%
Bullish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
69%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
68%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 7 days ago
64%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 13 days ago
69%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
71%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
74%
View a ticker or compare two or three
Ad is loading...
GLYCDaily Signal changed days agoGain/Loss if shorted
 
Show more...
IONSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALE63.100.09
+0.14%
ALLETE
STXS2.25N/A
N/A
Stereotaxis
OP2.50-0.02
-0.79%
OceanPal
KELYA23.48-0.19
-0.80%
Kelly Services
BAX36.12-0.39
-1.07%
Baxter International

GLYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLYC has been closely correlated with LYRA. These tickers have moved in lockstep 87% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLYC jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLYC
1D Price
Change %
GLYC100%
-3.20%
LYRA - GLYC
87%
Closely correlated
-19.46%
EYPT - GLYC
37%
Loosely correlated
+5.98%
AXON - GLYC
36%
Loosely correlated
-4.55%
IONS - GLYC
35%
Loosely correlated
-3.19%
MDGL - GLYC
34%
Loosely correlated
-7.48%
More

IONS and

Correlation & Price change

A.I.dvisor indicates that over the last year, IONS has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IONS
1D Price
Change %
IONS100%
-3.19%
AXON - IONS
43%
Loosely correlated
-4.55%
ROIV - IONS
42%
Loosely correlated
-1.90%
NTLA - IONS
42%
Loosely correlated
+0.67%
AGIO - IONS
41%
Loosely correlated
-1.26%
INZY - IONS
41%
Loosely correlated
-5.74%
More